Loading…
Japanese pharmaceutical company developing drugs in urology, diabetes and rare disease areas.
Japanese pharmaceutical company developing drugs in urology, diabetes and rare disease areas.
Sells prescription drugs in Japan through its own sales reps, with a mature urology treatment, silodosin, also licensed to overseas partners that pay royalties. It also in-licenses drugs for Japan from other companies rather than relying only on its own research.
In one line: A small/mid Japanese pharma, like a smaller Ono Pharmaceutical.
Moat: narrow (IP / patents). Patent-protected niche drugs, but a smaller pipeline than major domestic pharma peers.
Headquarters: Matsumoto, Japan · Founded: 1946 · Employees: 1,786
Size Kissei Pharmaceutical (4547.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $973M, the 745th largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥3,665 on 6 Nov 2026.
Performance Over six months the shares fell 16.2%, against -12.3% for the median peer and +1.8% for the Japan market (cap-weighted) — 8th lowest of 19 in its peer set.
Growth Revenue grew 5.9% over the last twelve months (peer median +2.4%); the operating margin is 5.8% (peer median 4.5%).
Valuation It trades at 12.0× forward earnings against a peer median of 24.5× (cheapest of 10).
Capital Return on invested capital runs 2.8 points below its cost of capital (5.0% WACC).
Next results Next results expected around 2 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥97.1B | ¥97.4B | ¥88.3B | ¥75.6B | ¥67.5B |
| Revenue growth | — | +10% | +17% | +12% | — |
| Gross profit | ¥44.8B | ¥43.0B | ¥41.0B | ¥34.4B | ¥29.7B |
| EBITDA | ¥10.4B | ¥1.72B | ¥10.6B | ¥8.27B | ¥2.97B |
| Net income | ¥11.2B | ¥13.8B | ¥12.0B | ¥11.2B | ¥10.5B |
| Free cash flow | n/a | -¥6.37B | ¥2.01B | -¥2.88B | -¥8.78B |
| Capital expenditure | n/a | ¥5.64B | ¥8.56B | ¥3.09B | ¥7.24B |
| Total debt | ¥1.25B | ¥1.48B | ¥1.60B | ¥1.73B | ¥1.95B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Kissei Pharmaceutical 4547.T | $973M | -16% | +6% | 6% | 12.0× | n/a |
| ONO Pharmaceutical 4528.T | $7.01B | +2% | -2% | 22% | 14.7× | -8.2% |
| Nippon Shinyaku 4516.T | $1.43B | -30% | +12% | 19% | 7.7× | -17.5% |
| Astellas Pharma 4503.T | $28.2B | +11% | +19% | 23% | 11.6× | -11.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4547.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.1% | -7.3% | 8th highest of 20 |
| 6-month return | -16.2% | -12.3% | 8th lowest of 19 |
| Distance from 52-week high | -27.3% | -34.0% | 8th highest of 21 |
| Revenue growth (TTM) | +5.9% | +2.4% | 8th highest of 18 |
| Operating margin | 5.8% | 4.5% | 9th highest of 18 |
| Forward P/E | 12.0× | 24.5× | cheapest of 10 |
| ROIC minus cost of capital | -2.8 pp | -1.9 pp | 7th lowest of 16 |
| EV / EBITDA | 9.9× | 19.4× | cheapest of 8 |
| Net debt / EBITDA | -5.1× | 2.1× | least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Kissei Pharmaceutical 4547.T | Japan | $973M | -16% | +6% | 6% | 12.0× | n/a | n/a |
| Strides Pharma Science STAR.NS | India | $973M | -13% | +11% | 14% | 15.5× | 18.1% | +7.8% |
| Jiangsu Yahong Meditech 688176.SS | China | $973M | -12% | +15% | -172% | n/a | n/a | n/a |
| Procter & Gamble Health PGHL.NS | India | $971M | +4% | +13% | 31% | 24.7× | 5.5% | +9.3% |
| MoonLake Immunotherapeutics MLTX | United States | $981M | -32% | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Garden Biopharmaceutical 300401.SZ | China | $983M | -7% | +2% | 24% | 24.4× | 10.2% | +13.4% |
| SSY 2005.HK | Hong Kong | $990M | +10% | -4% | 12% | 13.0× | 2.1% | -0.5% |
| Savara SVRA | United States | $992M | -8% | n/a | n/a | n/a | n/a | n/a |
| Immatics IMTX | United States | $952M | -44% | -65% | -556% | n/a | n/a | n/a |
| Northeast Pharmaceutical 000597.SZ | China | $948M | -10% | -6% | 3% | n/a | -6.8% | -0.7% |
| Harbin Gloria Pharmaceuticals 002437.SZ | China | $999M | -15% | -16% | 13% | n/a | 8.8% | -6.9% |
| City Therapeutics CTY | United States | $944M | n/a | +388% | -442% | n/a | n/a | n/a |
| KPC Pharmaceuticals 600422.SS | China | $1.00B | -7% | -41% | -10% | n/a | n/a | n/a |
| Hunan Warrant Pharmaceutical 688799.SS | China | $942M | -20% | +5% | 9% | 33.8× | n/a | n/a |
| Harrow HROW | United States | $1.01B | -30% | +21% | 2% | 21.9× | 51.8% | +41.0% |
| Nxera Pharma 4565.T | Japan | $932M | +63% | +24% | 14% | 24.5× | 16.2% | +27.3% |
| GuangYuYuan Chinese Herbal Medicine 600771.SS | China | $930M | -24% | -6% | 5% | 41.1× | 33.2% | +4.2% |
| Dezhan Healthcare 000813.SZ | China | $928M | -18% | -10% | -121% | n/a | n/a | n/a |
| Oscotec 039200.KS | South Korea | $1.02B | -30% | +233% | 62% | 56.8× | -9.5% | +18.1% |
| Guangxi Wuzhou Zhongheng 600252.SS | China | $1.03B | -11% | -43% | -42% | n/a | 11.9% | -13.7% |
| Symbiotec Pharmalab SYMBIOTEC.NS | India | $1.03B | n/a | n/a | n/a | n/a | n/a | n/a |